Literature DB >> 28163556

New Pharmacotherapies in Chronic Lymphocytic Leukemia.

Jacqueline L Olin, Katherine Canupp, Morgan B Smith.   

Abstract

The authors present the clinical outcomes and therapeutic application of newly approved pharmacotherapies for chronic lymphocytic leukemia and highlight emerging investigational therapeutic options.

Entities:  

Year:  2017        PMID： 28163556      PMCID： PMC5265236     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  61 in total

1.  Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial.

Authors:  Kirsten Fischer; Jasmin Bahlo; Anna Maria Fink; Valentin Goede; Carmen Diana Herling; Paula Cramer; Petra Langerbeins; Julia von Tresckow; Anja Engelke; Christian Maurer; Gabor Kovacs; Marco Herling; Eugen Tausch; Karl-Anton Kreuzer; Barbara Eichhorst; Sebastian Böttcher; John F Seymour; Paolo Ghia; Paula Marlton; Michael Kneba; Clemens-Martin Wendtner; Hartmut Döhner; Stephan Stilgenbauer; Michael Hallek
Journal:  Blood       Date:  2015-10-20       Impact factor: 22.113

2.  The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20.

Authors:  Jessica L Teeling; Wendy J M Mackus; Luus J J M Wiegman; Jeroen H N van den Brakel; Stephen A Beers; Ruth R French; Tom van Meerten; Saskia Ebeling; Tom Vink; Jerry W Slootstra; Paul W H I Parren; Martin J Glennie; Jan G J van de Winkel
Journal:  J Immunol       Date:  2006-07-01       Impact factor: 5.422

3.  ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.

Authors:  Andrew J Souers; Joel D Leverson; Erwin R Boghaert; Scott L Ackler; Nathaniel D Catron; Jun Chen; Brian D Dayton; Hong Ding; Sari H Enschede; Wayne J Fairbrother; David C S Huang; Sarah G Hymowitz; Sha Jin; Seong Lin Khaw; Peter J Kovar; Lloyd T Lam; Jackie Lee; Heather L Maecker; Kennan C Marsh; Kylie D Mason; Michael J Mitten; Paul M Nimmer; Anatol Oleksijew; Chang H Park; Cheol-Min Park; Darren C Phillips; Andrew W Roberts; Deepak Sampath; John F Seymour; Morey L Smith; Gerard M Sullivan; Stephen K Tahir; Chris Tse; Michael D Wendt; Yu Xiao; John C Xue; Haichao Zhang; Rod A Humerickhouse; Saul H Rosenberg; Steven W Elmore
Journal:  Nat Med       Date:  2013-01-06       Impact factor: 53.440

4.  A phase I study of lenalidomide in combination with fludarabine and rituximab in previously untreated CLL/SLL.

Authors:  J R Brown; J Abramson; E Hochberg; E Mikler; V Dalton; L Werner; H Reynolds; C Thompson; S M McDonough; Y Kuang; J Ritz; D Neuberg; A S Freedman
Journal:  Leukemia       Date:  2010-09-16       Impact factor: 11.528

5.  Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia.

Authors:  Carol Moreno; Marco Montillo; Panayiotis Panayiotidis; Maria Dimou; Adrian Bloor; Jehan Dupuis; Anna Schuh; Stefan Norin; Christian Geisler; Peter Hillmen; Michael Doubek; Marek Trněný; Petra Obrtlikova; Luca Laurenti; Stephan Stilgenbauer; Lukas Smolej; Paolo Ghia; Florence Cymbalista; Ulrich Jaeger; Kostas Stamatopoulos; Niki Stavroyianni; Patrick Carrington; Hamadi Zouabi; Veronique Leblond; Juan C Gomez-Garcia; Martin Rubio; Roberto Marasca; Gerardo Musuraca; Luigi Rigacci; Lucia Farina; Rossella Paolini; Sarka Pospisilova; Eva Kimby; Colm Bradley; Emili Montserrat
Journal:  Haematologica       Date:  2015-01-16       Impact factor: 9.941

Review 6.  Advances in first-line treatment of chronic lymphocytic leukemia: current recommendations on management and first-line treatment by the German CLL Study Group (GCLLSG).

Authors:  Paula Cramer; Petra Langerbeins; Barbara Eichhorst; Michael Hallek
Journal:  Eur J Haematol       Date:  2015-11-06       Impact factor: 2.997

7.  Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemia.

Authors:  Christian Maurer; Natali Pflug; Jasmin Bahlo; Sandra Kluth; Christina Rhein; Paula Cramer; Carolin Gross-Ophoff; Petra Langerbeins; Anna-Maria Fink; Barbara Eichhorst; Karl-Anton Kreuzer; Norbert Fischer; Eugen Tausch; Stephan Stilgenbauer; Sebastian Böttcher; Hartmut Döhner; Michael Kneba; Martin Dreyling; Mascha Binder; Michael Hallek; Clemens-Martin Wendtner; Manuela Bergmann; Kirsten Fischer
Journal:  Eur J Haematol       Date:  2016-02-09       Impact factor: 2.997

8.  Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.

Authors:  Andrew W Roberts; Matthew S Davids; John M Pagel; Brad S Kahl; Soham D Puvvada; John F Gerecitano; Thomas J Kipps; Mary Ann Anderson; Jennifer R Brown; Lori Gressick; Shekman Wong; Martin Dunbar; Ming Zhu; Monali B Desai; Elisa Cerri; Sari Heitner Enschede; Rod A Humerickhouse; William G Wierda; John F Seymour
Journal:  N Engl J Med       Date:  2015-12-06       Impact factor: 91.245

9.  Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemia.

Authors:  Julio C Chavez; Miguel Piris-Villaespesa; Samir Dalia; John Powers; Elyce Turba; Lisa Nodzon; Rami Komrokji; Lubomir Sokol; Frederick L Locke; Jeffrey Lancet; Eduardo M Sotomayor; Mohamed A Kharfan-Dabaja; Javier Pinilla-Ibarz
Journal:  Leuk Res       Date:  2016-05-17       Impact factor: 3.156

10.  Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase Cdelta.

Authors:  Ingo Ringshausen; Folker Schneller; Christian Bogner; Susanne Hipp; Justus Duyster; Christian Peschel; Thomas Decker
Journal:  Blood       Date:  2002-07-12       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.